Pharmac Decision: Methylphenidate Sandoz XR to be funded from 1 December 2025

Pharmac has confirmed it will fund an additional extended-release brand of methylphenidate - Methylphenidate Sandoz XR - from 1 December 2025.  This decision follows recent consultation and will help increase supply and provide more options for people who need ADHD treatments.

Methylphenidate Sandoz XR will be available in the same strengths as Concerta – 18 mg, 27 mg, 36 mg, and 54 mg. It will be funded alongside currently available brands, under existing eligibility criteria.You can read the full decision and summary of feedback on our website:

• Decision to fund a new brand of methylphenidate

  
  

Thank you to everyone who shared their views. Your feedback has been invaluable in helping us make a well-informed decision that reflects the needs and concerns of people who use ADHD medicines.

Ngā mihi,

Ashleigh Kleinsman (she/her)| Therapeutic Group Manager

Pharmac | Te Pātaka Whaioranga | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington

P: 0800 660 050 | www.pharmac.govt.nz